← All companies

AGMB

AgomAb Therapeutics NV

AGMB Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$13.52

+0.65 +5.05%

Key statistics

from XBRL data in SEC filings

Market cap

$462M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

—

Total assets

—

Gross margin

—

52-week range

$8.75 – $17.82

Recent SEC filings

33 most recent

Annual, quarterly & current reports

6-K FORM 6-K Jun 23, 2026 6-K FORM 6-K May 27, 2026 6-K FORM 6-K Apr 24, 2026 20-F FORM 20-F Apr 23, 2026 6-K FORM 6-K Mar 5, 2026 6-K FORM 6-K Feb 9, 2026

Other filings

SCHEDULE 13G May 15, 2026 SCHEDULE 13G May 15, 2026 SCHEDULE 13G May 6, 2026 SCHEDULE 13G Apr 16, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 3 OWNERSHIP DOCUMENT Mar 18, 2026 S-8 FORM S-8 Mar 11, 2026 SCHEDULE 13G Mar 6, 2026 SCHEDULE 13D Feb 17, 2026 424B4 Feb 6, 2026 CERT Feb 5, 2026 8-A12B FORM 8-A12B Feb 3, 2026 EFFECT Jan 30, 2026 F-1/A Jan 29, 2026 F-1 Jan 16, 2026 DRS/A Dec 17, 2025 DRS/A Oct 28, 2025 DRS Jun 20, 2024